» Articles » PMID: 32932674

Brown Seaweeds for the Management of Metabolic Syndrome and Associated Diseases

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2020 Sep 16
PMID 32932674
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic syndrome is characterized by the coexistence of different metabolic disorders which increase the risk of developing type 2 diabetes mellitus and cardiovascular diseases. Therefore, metabolic syndrome leads to a reduction in patients' quality of life as well as to an increase in morbidity and mortality. In the last few decades, it has been demonstrated that seaweeds exert multiple beneficial effects by virtue of their micro- and macronutrient content, which could help in the management of cardiovascular and metabolic diseases. This review aims to provide an updated overview on the potential of brown seaweeds for the prevention and management of metabolic syndrome and its associated diseases, based on the most recent evidence obtained from in vitro and in vivo preclinical and clinical studies. Owing to their great potential for health benefits, brown seaweeds are successfully used in some nutraceuticals and functional foods for treating metabolic syndrome comorbidities. However, some issues still need to be tackled and deepened to improve the knowledge of their ADME/Tox profile in humans, in particular by finding validated indexes of their absorption and obtaining reliable information on their efficacy and long-term safety.

Citing Articles

Biomarkers and Seaweed-Based Nutritional Interventions in Metabolic Syndrome: A Comprehensive Review.

Valado A, Cunha M, Pereira L Mar Drugs. 2024; 22(12).

PMID: 39728125 PMC: 11677938. DOI: 10.3390/md22120550.


Investigation of Biological Activity of Fucoidan and Laminarin as Bioactive Polysaccharides from Irish Brown Macroalgae.

Karuppusamy S, Wanigasekara J, Fitzpatrick S, Lyons H, Curtin J, Rajauria G Cells. 2024; 13(23).

PMID: 39682687 PMC: 11640187. DOI: 10.3390/cells13231938.


Marine Pharmacology in 2019-2021: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis and Antiviral Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous....

Mayer A, Mayer V, Swanson-Mungerson M, Pierce M, Rodriguez A, Nakamura F Mar Drugs. 2024; 22(7).

PMID: 39057418 PMC: 11278370. DOI: 10.3390/md22070309.


Natural products for managing metabolic syndrome: a scoping review.

Abdulghani M, Al-Fayyadh S Front Pharmacol. 2024; 15:1366946.

PMID: 38746011 PMC: 11091304. DOI: 10.3389/fphar.2024.1366946.


Seaweeds as Nutraceutical Elements and Drugs for Diabetes Mellitus: Future Perspectives.

Cotas J, Lomartire S, Pereira L, Valado A, Marques J, Goncalves A Mar Drugs. 2024; 22(4).

PMID: 38667785 PMC: 11051413. DOI: 10.3390/md22040168.


References
1.
Golomb B, Evans M . Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2009; 8(6):373-418. PMC: 2849981. DOI: 10.2165/0129784-200808060-00004. View

2.
Simopoulos A . An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk for Obesity. Nutrients. 2016; 8(3):128. PMC: 4808858. DOI: 10.3390/nu8030128. View

3.
Park S, Kim J, Jang H, Yang S, Kim Y . Inhibitory activity of minor phlorotannins from Ecklonia cava on α-glucosidase. Food Chem. 2018; 257:128-134. DOI: 10.1016/j.foodchem.2018.03.013. View

4.
Mikami N, Hosokawa M, Miyashita K, Sohma H, Ito Y, Kokai Y . Reduction of HbA1c levels by fucoxanthin-enriched akamoku oil possibly involves the thrifty allele of uncoupling protein 1 (): a randomised controlled trial in normal-weight and obese Japanese adults. J Nutr Sci. 2017; 6:e5. PMC: 5465861. DOI: 10.1017/jns.2017.1. View

5.
Lopez-Lopez I, Bastida S, Ruiz-Capillas C, Bravo L, Larrea M, Sanchez-Muniz F . Composition and antioxidant capacity of low-salt meat emulsion model systems containing edible seaweeds. Meat Sci. 2010; 83(3):492-8. DOI: 10.1016/j.meatsci.2009.06.031. View